Ajinomoto, AstraZeneca: expanded manufacturing agreement
Ajinomoto Bio-Pharma Services has announced an expansion of its existing agreement with AstraZeneca to include drug product manufacturing. The expanded scope now includes aseptic fill finish services at Ajinomoto’s San Diego, California facility, as well as small-molecule manufacturing services in Belgium.
“We are excited to expand our manufacturing agreement with AstraZeneca and to support them with additional service offerings," said Magnus Busch, global account manager for Ajinomoto Bio-Pharma Services. “This expanded agreement builds on our commitment to be a leading, trusted, innovative partner to our clients.”
